XTL Biopharmaceuticals Ltd. (XTLB)

Last Closing Price: 1.24 (2022-12-08)

Company Description

XTL Biopharmaceuticals Ltd. is a biopharmaceutical company developing drugs against hepatitis.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $0.44M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) 6.19
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 1.42
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 15.48
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) 30.70%
Return on Assets (Trailing 12 Months) 23.53%
Current Ratio (Most Recent Fiscal Quarter) 29.52
Quick Ratio (Most Recent Fiscal Quarter) 31.26
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $0.98
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) $0.20
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 5.45M
Free Float 3.87M
Market Capitalization $6.75M
Average Volume (Last 20 Days) 2894.70
Beta (Past 60 Months) 1.27
Percentage Held By Insiders (Latest Annual Proxy Report) 29.00%
Percentage Held By Institutions (Latest 13F Reports) 8.21%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%